Reading the last study, where people started glps after diagnosis, made me think about how difficult cancer and treatment for cancer is, and then adding the side effects of glps on top of that sounds awful. Cancer patients deserve better than this. Posters are great, but they aren't a peer reviewed article.
This was a great read, and pulling each author's OpenPayments record against their ASCO disclosures is the kind of legwork these write-ups almost never do.
The detail that stuck with me was your note that SGLT2 inhibitors showed the same association in an earlier study, yet this one only benchmarked GLP-1s against DPP-4. When two mechanistically unrelated drug classes both 'protect,' the shared variable is usually the patient who gets prescribed either one, not the molecule. That, plus the breast cancer signal holding independent of BMI, makes the weight-loss story the discussion sections reach for hard to sustain.
Thank you so much for your dedication and hard work! This series was eye opening.
Here’s hoping there’s a shift in the field and we start seeing more validated research that gives us some actual evidence to guide the patients navigating this mess.
Reading the last study, where people started glps after diagnosis, made me think about how difficult cancer and treatment for cancer is, and then adding the side effects of glps on top of that sounds awful. Cancer patients deserve better than this. Posters are great, but they aren't a peer reviewed article.
Totally agree.
This was a great read, and pulling each author's OpenPayments record against their ASCO disclosures is the kind of legwork these write-ups almost never do.
The detail that stuck with me was your note that SGLT2 inhibitors showed the same association in an earlier study, yet this one only benchmarked GLP-1s against DPP-4. When two mechanistically unrelated drug classes both 'protect,' the shared variable is usually the patient who gets prescribed either one, not the molecule. That, plus the breast cancer signal holding independent of BMI, makes the weight-loss story the discussion sections reach for hard to sustain.
Thank you so much for your dedication and hard work! This series was eye opening.
Here’s hoping there’s a shift in the field and we start seeing more validated research that gives us some actual evidence to guide the patients navigating this mess.